Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

NCT07220252 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG: Ublituximab
DRUG: Placebo
DRUG: Placebo
DRUG: Fingolimod

Sponsor

TG Therapeutics, Inc.